<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">GAN</journal-id>
<journal-id journal-id-type="hwp">spgan</journal-id>
<journal-title>Genes &amp; Cancer</journal-title>
<issn pub-type="ppub">1947-6019</issn>
<issn pub-type="epub">1947-6027</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1947601912473479</article-id>
<article-id pub-id-type="publisher-id">10.1177_1947601912473479</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Monographs</subject>
<subj-group subj-group-type="heading">
<subject>Mechanisms of Regulation that Operate Through the Cell Cycle</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs</article-title>
<subtitle>Potential Implications for PP2A Disruption in Cancer</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kurimchak</surname><given-names>Alison</given-names></name>
<xref ref-type="aff" rid="aff1-1947601912473479">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Graña</surname><given-names>Xavier</given-names></name>
<xref ref-type="aff" rid="aff1-1947601912473479">1</xref>
<xref ref-type="aff" rid="aff2-1947601912473479">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1947601912473479"><label>1</label>Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, USA</aff>
<aff id="aff2-1947601912473479"><label>2</label>Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA, USA</aff>
<author-notes>
<corresp id="corresp1-1947601912473479">Xavier Graña, Fels Institute for Cancer Research and Molecular Biology, Department of Biochemistry, Temple University School of Medicine, AHP Bldg, Room 308, 3307 North Broad St, Philadelphia, PA 19140 (Email: <email>xavier@temple.edu</email>).</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>11-12</issue>
<fpage>739</fpage>
<lpage>748</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Protein Phosphatase 2A (PP2A) consists of a collection of heterotrimeric serine/threonine phosphatase holoenzymes that play multiple roles in cell signaling via dephosphorylation of numerous substrates of a large family of serine/threonine kinases. PP2A substrate specificity is mediated by B regulatory subunits of four different families, which selectively recognize diverse substrates by mechanisms that are not well understood. Among the many signaling pathways with critical PP2A functions are several deregulated in cancer cells, and PP2A is a know tumor suppressor. However, the precise composition of the heterotrimeric PP2A complexes with tumor supressor activity is not well understood. This review is centered on the emerging role of the B regulatory subunit B55α and related subfamilly members in the modulation of the phosphorylation state of pocket proteins and mitotic CDK substrates, as well as the implications of PP2A function disruption in cancer in the context of these activities.</p>
</abstract>
<kwd-group>
<kwd>cyclins</kwd>
<kwd>p107</kwd>
<kwd>p130</kwd>
<kwd>PPP2R2A</kwd>
<kwd>B55α</kwd>
<kwd>tumor suppressor</kwd>
<kwd>PP2A inhibitors</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>November/December 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-1947601912473479" sec-type="intro">
<title>Introduction</title>
<p>Protein Phosphatase 2A (PP2A) is an abundant serine/threonine phosphatase, which attains substrate specificity via the assembly of a large pool of holoenzymes consisting at the minimum of three subunits. A catalytic subunit (PP2A/C) and a scaffold subunit (PP2A/A), each encoded by two different genes, form core dimers, which are assembled with a collection of PP2A/B regulatory subunits forming trimeric holoenzymes (<xref ref-type="fig" rid="fig1-1947601912473479">Figure 1</xref>). B subunits belong to four separate families, designated B, B′, B′′ and B′′′, each with multiple members encoded by different genes. The crystal structure of two separate holoenzymes assembled with regulatory subunits of the B (B55α) or the B′ (B56g) families, has provided insight on how the B subunit forms a pocket with the catalytic subunit that may confer substrate specificity<sup><xref ref-type="bibr" rid="bibr1-1947601912473479">1</xref><xref ref-type="bibr" rid="bibr2-1947601912473479"/>-<xref ref-type="bibr" rid="bibr3-1947601912473479">3</xref></sup>. PP2A plays a major role in signaling by counteracting the action of Ser/Thr kinases in multiple pathways and is implicated in a large number of cellular processes including those that are often defective in cancer. Major targets of relevance to cancer include the MAP kinase and AKT pathways, the tumor suppressors pRB and p53, and CDK1 substrates among others<sup><xref ref-type="bibr" rid="bibr3-1947601912473479">3</xref><xref ref-type="bibr" rid="bibr4-1947601912473479"/>-<xref ref-type="bibr" rid="bibr5-1947601912473479">5</xref></sup>. This review is mainly focused on the emerging role of B55α and perhaps other members of the B family in the modulation of the phosphorylation state of pocket proteins and mitotic CDK substrates, as well as the implications of PP2A function disruption in cancer in the context of these activities. Recent reviews focused on the role of serine/threonine phosphatases in the regulation of pocket protein function have been published recently<sup><xref ref-type="bibr" rid="bibr3-1947601912473479">3</xref>,<xref ref-type="bibr" rid="bibr5-1947601912473479">5</xref></sup>.</p>
<fig id="fig1-1947601912473479" position="float">
<label>Figure 1.</label>
<caption>
<p>Heterotrimeric PP2A holoenzymes consist of a catalytic, a scaffold, and a regulatory subunit. The B regulatory subunit is responsible for substrate specificity and/or subcellular localization and can be any member from 4 unrelated families (B, B’, B’’, and B’’’). Scaffold and catalytic subunits are encoded each by 2 separate genes. Gene symbols and common protein names are listed.</p>
</caption>
<graphic xlink:href="10.1177_1947601912473479-fig1.tif"/>
</fig>
</sec>
<sec id="section2-1947601912473479">
<title>Evidence That PP2A Is a Tumor Suppressor</title>
<p>Early evidence suggesting that PP2A could function as a tumor suppressor comes from studies showing that okadaic acid (OA) and other toxins in the same family that inhibit PP2A promote tumors in mice and the finding that SV-40 small t antigen, which inhibits PP2A, can transform human cells in cooperation with other oncogenes and facilitates transformation of rodent cells.</p>
<sec id="section3-1947601912473479">
<title>Toxins that inhibit PP2A are potent tumor promoters</title>
<p>OA is a toxin extracted from marine sponges and is one of the causative agents of diarrheic shellfish poisoning.<sup><xref ref-type="bibr" rid="bibr6-1947601912473479">6</xref></sup> OA was shown to inhibit PP2A, PP2B, and PP1 <italic>in vitro</italic>, with ID<sub>50</sub>s in the nanomolar and micromolar ranges for PP2A and PP1, respectively.<sup><xref ref-type="bibr" rid="bibr7-1947601912473479">7</xref></sup> OA was also found to induce skin irritation in mice in a screen for tumor promoters<sup><xref ref-type="bibr" rid="bibr8-1947601912473479">8</xref></sup> using a 2-stage carcinogenesis protocol.<sup><xref ref-type="bibr" rid="bibr9-1947601912473479">9</xref></sup> In this carcinogenesis experimental system, in which mice were treated with DMBA (a tumor initiator) followed by OA (tumor promoter), 93% of the mice displayed tumors by week 16 in a 30-week treatment. Of note, this was not mediated via activation of PKC, indicating that its mechanism of action was different from that of TPA-tumor promoters.<sup><xref ref-type="bibr" rid="bibr9-1947601912473479">9</xref></sup> Calyculin A, another potent PP1/PP2A inhibitor isolated from marine sponges, was found to have tumor-promoting activity in mice comparable to that of OA<sup><xref ref-type="bibr" rid="bibr10-1947601912473479">10</xref></sup>; however, Calyculin A appeared to inhibit PP1 and PP2A with comparable potency.<sup><xref ref-type="bibr" rid="bibr11-1947601912473479">11</xref></sup> Other inhibitors of PP1/PP2A, microcystin-LR and tautomycin, were subsequently identified that were equally potent toward both types of serine/threonine protein phosphatases.<sup><xref ref-type="bibr" rid="bibr12-1947601912473479">12</xref></sup></p>
</sec>
<sec id="section4-1947601912473479">
<title>The transforming activities of the small t antigens (st) of SV40 and related polyomaviruses are mediated via PP2A inhibition</title>
<p>SV40 and related polyomaviruses encode tumor antigens that target and inhibit tumor suppressors in mammalian cells, and this results in their immortalization and/or transformation.<sup><xref ref-type="bibr" rid="bibr13-1947601912473479">13</xref></sup> The small t antigen (st) of SV40 and the small and middle T antigens of polyomaviruses were found to interact with 2 cellular proteins, 36 and 63 kD in size,<sup><xref ref-type="bibr" rid="bibr14-1947601912473479">14</xref><xref ref-type="bibr" rid="bibr15-1947601912473479"/>-<xref ref-type="bibr" rid="bibr16-1947601912473479">16</xref></sup> which appeared important for transformation, as a middle T transformation-defective mutant was unable to form a complex with the 63 kD protein.<sup><xref ref-type="bibr" rid="bibr17-1947601912473479">17</xref></sup> Peptide microsequencing, co-migration in 2D gels, limited proteolysis, and Western blot analyses were used to identify these proteins as the scaffold and catalytic subunits of PP2A,<sup><xref ref-type="bibr" rid="bibr18-1947601912473479">18</xref>,<xref ref-type="bibr" rid="bibr19-1947601912473479">19</xref></sup> hence implicating PP2A in oncogenic transformation of mammalian cells. Importantly, no B subunits were identified associated with these tumor antigens. It was later shown that st interacts directly with the amino terminal HEAT domains present in the PP2A/A scaffold subunit. This association does not interfere with binding of PP2A/C, which interacts with the C-terminal HEAT domains of PP2A/A, but appears to compete with B regulatory subunits, as these also interact with the amino-terminal HEAT domains of PP2A/A.<sup><xref ref-type="bibr" rid="bibr20-1947601912473479">20</xref></sup> This competition was elegantly observed <italic>in vitro</italic>, as purified ERK and MEK treated with PP2A/B55α heterotrimers preincubated with an excess of st were as potently inactivated as if the PP2A/B55α treatment had been done in the presence of OA.<sup><xref ref-type="bibr" rid="bibr21-1947601912473479">21</xref></sup> In contrast, st did not affect the purified active free PP2A/C catalytic subunit and affected PP2A A-C dimers to a lower extent in the same assay. Moreover, the ability of st to compete with B subunits in cells for binding to PP2A A-C dimers has been shown in cells and may be specific to particular heterotrimers,<sup><xref ref-type="bibr" rid="bibr21-1947601912473479">21</xref><xref ref-type="bibr" rid="bibr22-1947601912473479"/>-<xref ref-type="bibr" rid="bibr23-1947601912473479">23</xref></sup> suggesting a mechanism by which st may inhibit dephosphorylation of a subset of PP2A substrates. It has also been shown that the binding of st to the core dimer inhibits PP2A′s enzymatic activity toward multiple substrates.<sup><xref ref-type="bibr" rid="bibr20-1947601912473479">20</xref>,<xref ref-type="bibr" rid="bibr24-1947601912473479">24</xref></sup> More recently, a crystal structure of st in complex with the PP2A core dimer showed that st has 2 C-terminal zinc binding motifs. One of these motifs and the N-terminal J domain of st overlap the site where the B56γ subunit binds the scaffold subunit. In contrast, the other zinc binding motif is positioned in a manner that may inhibit the catalytic activity of the C subunit,<sup><xref ref-type="bibr" rid="bibr25-1947601912473479">25</xref></sup> suggesting that both B subunit displacement and direct inhibition of PP2A/C may mediate the effects of st on PP2A. In contrast, another study showed that <italic>in vitro</italic>, st does not efficiently displace B subunits from heterotrimeric complexes unless st is in excess. However, as pointed out by the authors of the study, the J domain of st has been shown to interact with HSC70 increasing its activity, which hypothetically might help disassemble heterotrimers in cells.<sup><xref ref-type="bibr" rid="bibr26-1947601912473479">26</xref></sup></p>
<p>It is also important to underscore the critical role of the pathways inactivated by st in the transformation of human cells. Human cells are more difficult to both immortalize and transform than rodent cells, which often spontaneously immortalize and even transform as passaged extensively in culture. Transformation of normal human fibroblasts, mammary epithelial cells, and kidney epithelial (HEK) cells can be accomplished via expression of the early region of SV40, oncogenic H-RAS, and expression of catalytic subunit of human telomerase (hTERT).<sup><xref ref-type="bibr" rid="bibr27-1947601912473479">27</xref></sup> The early region of SV40 encodes the large antigen (LT), which disables both the pRB and p53 pathways, and st, which inhibits PP2A.<sup><xref ref-type="bibr" rid="bibr28-1947601912473479">28</xref></sup> In these cells, st promotes proliferation, even with nutrient deprivation, and permits anchorage independent growth and tumor formation in immunocompromised mice.<sup><xref ref-type="bibr" rid="bibr29-1947601912473479">29</xref></sup> Subsequently, it was shown that in HEK cells immortalized with LT, hTERT, and H-RAS, knockdown of B56γ3, a regulatory subunit of PP2A from the B′ family, substitutes for st in the anchorage independent and tumorigenicity assays described above.<sup><xref ref-type="bibr" rid="bibr22-1947601912473479">22</xref></sup> Reciprocally, ectopic expression of B56γ3 in HEK cells expressing LT, hTERT, H-RAS, and st inhibited tumorigenicity. Importantly, reintroduction of B56γ3 in lung cancer cell lines that expressed no detectable levels of this B subunit reduced cell proliferation and anchorage independent growth. Thus, this study identified PP2A/B56γ3 holoenzymes as one of the key targets of st in HEK cells, as HEK cells with reduced B55α do not behave in the same manner. A later study using a panel of shRNAs targeting various B subunits demonstrated that the loss of B56α, B56γ, PR72/PR130, and PTPA in immortalized HEK cells results in increased anchorage-independent colony formation as well as the activation of the PI3K/AKT, c-MYC, and WNT pathways.<sup><xref ref-type="bibr" rid="bibr30-1947601912473479">30</xref></sup></p>
</sec>
<sec id="section5-1947601912473479">
<title>Adenovirus E4ORF4 modulates the activity of B55α trimeric PP2A holoenzymes</title>
<p>Another viral protein known to target PP2A is the adenoviral protein E4ORF4, which directly binds to the B55 subunit,<sup><xref ref-type="bibr" rid="bibr31-1947601912473479">31</xref></sup> and this interaction is required for E4ORF4-mediated apoptosis, which is independent of p53.<sup><xref ref-type="bibr" rid="bibr32-1947601912473479">32</xref></sup> As opposed to SV40 st, E4ORF4 forms complexes with PP2A heterotrimers via direct interaction with the B subunit and may direct PP2A to substrates, a mechanism that is significantly different than that described above for st. Members of the B′ regulatory subunit family also bind E4ORF4, but E4ORF4-mediated apoptosis is dependent on E4ORF4 binding to B55α.<sup><xref ref-type="bibr" rid="bibr33-1947601912473479">33</xref><xref ref-type="bibr" rid="bibr34-1947601912473479"/>-<xref ref-type="bibr" rid="bibr35-1947601912473479">35</xref></sup> E4ORF4 also downregulates <italic>MYC</italic> transcription by targeting B55α.<sup><xref ref-type="bibr" rid="bibr36-1947601912473479">36</xref></sup> Moreover, E4ORF4 has been shown to induce G2/M arrest and mitotic catastrophe, and this may result from a decrease in the global activity of B55α PP2A heterotrimers.<sup><xref ref-type="bibr" rid="bibr37-1947601912473479">37</xref></sup> This is consistent with a critical role for B55α in mitotic exit (see below). Although it appears counteractive that a viral protein might be that toxic to cells, it has been proposed that this facet of E4orf4 may facilitate release of the viral progeny.<sup><xref ref-type="bibr" rid="bibr38-1947601912473479">38</xref></sup></p>
</sec>
<sec id="section6-1947601912473479">
<title>PP2A activity can also be inhibited by endogenous inhibitors that are deregulated in cancer</title>
<p>PP2A activity can also be deregulated in cancer via endogenous inhibitors such as Cancerous Inhibitor of PP2A (CIP2A) and I2PP2A/SET. CIP2A was first identified as a 90 kD protein (p90) recognized by auto-antibodies detected in the sera of hepatocellular carcinoma and gastric cancer patients but not in normal human serum.<sup><xref ref-type="bibr" rid="bibr39-1947601912473479">39</xref></sup> The cellular function of p90 and relation to malignancy were unveiled when it was identified as a PP2A-interacting protein in a tandem mass spectrometric analysis and renamed CIP2A. As MYC protein stability had been previously linked to PP2A destabilizing dephosphorylation of serine 62 (S62) on MYC,<sup><xref ref-type="bibr" rid="bibr40-1947601912473479">40</xref>,<xref ref-type="bibr" rid="bibr41-1947601912473479">41</xref></sup> the effect of CIP2A knockdown was investigated. CIP2A siRNA reduced MYC-S62 phosphorylation and MYC expression and increased PP2A association with MYC, suggesting that CIP2A facilitates MYC stability by inhibiting PP2A.<sup><xref ref-type="bibr" rid="bibr42-1947601912473479">42</xref></sup> Consistent with its MYC-stabilizing function, CIP2A was found to be overexpressed in head and neck squamous cell carcinomas (HNSCC); to be able to substitute for st in transformation of HEK cells expressing hTERT, LT, and oncogenic RAS; and to promote tumorigenesis in HNSCC cells. Moreover, expression of CIP2A was associated with reduced survival in gastric cancer patients and with breast cancer aggressivity, suggesting a prognostic value for CIP2A levels in these cancers.<sup><xref ref-type="bibr" rid="bibr43-1947601912473479">43</xref><xref ref-type="bibr" rid="bibr44-1947601912473479"/>-<xref ref-type="bibr" rid="bibr45-1947601912473479">45</xref></sup></p>
<p>Another endogenous inhibitor of PP2A, I2PP2A, was first purified from bovine kidney along with I1PP2A, and both were shown to inhibit PP2A activity <italic>in vitro</italic>.<sup><xref ref-type="bibr" rid="bibr46-1947601912473479">46</xref></sup> Subsequently, I2PP2A was found to be a truncated form of a protein designated SET.<sup><xref ref-type="bibr" rid="bibr47-1947601912473479">47</xref></sup> Importantly, in acute myeloid leukemia (AML), the <italic>SET</italic> gene is fused to the <italic>NUP214</italic> gene resulting in a chimeric SET-NUP214 protein,<sup><xref ref-type="bibr" rid="bibr48-1947601912473479">48</xref></sup> implicating I2PP2A/SET in deregulation of PP2A activity in leukemia. Next, SET was found to be induced by BCR-ABL in chronic myelogenous leukemia (CML), which results in PP2A inhibition. This in turn results in stabilization of BCR-ABL and stimulation of its downstream signaling pathways. In addition, BCR-ABL mediated upregulation of SET may inhibit attenuation of MAP kinase pathways by PP2A.<sup><xref ref-type="bibr" rid="bibr44-1947601912473479">44</xref>,<xref ref-type="bibr" rid="bibr49-1947601912473479">49</xref></sup> Consequently, forced upregulation of PP2A activity suppresses BCR-ABL oncogenicity <italic>in vitro</italic> and impairs leukemogenesis in SCID mice injected with 32D cells expressing BCR-ABL. Interestingly, pharmacological activation of PP2A with forskolin in these mice increased survival significantly, suggesting a potential new therapeutic avenue (see below).</p>
</sec>
</sec>
<sec id="section7-1947601912473479">
<title>PP2A Is a Haploinsufficient Tumor Suppressor</title>
<p>Mutations have also been found in the 2 genes (<italic>PPP2R1A</italic> and <italic>PPP2R1B</italic>) encoding the scaffolding PP2A/A subunit in several types of cancers (<xref ref-type="table" rid="table1-1947601912473479">Table 1</xref>). In one study, the <italic>PPP2R1B</italic> locus was analyzed in primary lung and colon samples as well as lung cancer derived cell lines. Various point and frameshift mutations were identified, including a mutant PP2A/Aβ scaffold subunit in a small cell lung cancer line that was unable to bind PP2A/C.<sup><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></sup> Another study analyzed breast, lung, and melanoma tumors and cell lines and found mutations in both <italic>PPP2R1A</italic> and <italic>PPP2R1B</italic>.<sup><xref ref-type="bibr" rid="bibr51-1947601912473479">51</xref></sup> The most frequent mutation found in this study, the deletion of exon 9 in <italic>PPP2R1B</italic>, results in the deletion of helix 9, which is needed for the binding of the B subunit.<sup><xref ref-type="bibr" rid="bibr52-1947601912473479">52</xref></sup> Recapitulation of mutations of the Aα<sup><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></sup> and Aβ<sup><xref ref-type="bibr" rid="bibr54-1947601912473479">54</xref></sup> scaffold subunits described by Calin <italic>et al</italic>.<sup><xref ref-type="bibr" rid="bibr51-1947601912473479">51</xref></sup> via site-directed mutagenesis and investigation of their effects on the integrity of various PP2A heterotrimers revealed defects in the binding of various B family member subunits as well as the catalytic subunit. Interestingly, the E64D and E64G mutations of the PP2A/Aα subunit are unable to bind members of the B′ family, whereas binding to B and B′′ members as well as the C subunit is relatively unaffected. Mutations in the C-terminal end are deficient in binding both B and C subunits.<sup><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></sup> Subsequently, it was shown that although PP2A/Aα mutants ectopically expressed in HEK-TER cells exhibited defects in binding other PP2A subunits, they were not oncogenic in transformation assays in which inactivation of PP2A by other means is transforming.<sup><xref ref-type="bibr" rid="bibr55-1947601912473479">55</xref></sup> In contrast, knockdown of the PP2A/Aα subunit in these cells promotes survival via activation of the AKT pathway and induced tumorigenesis in immunocompromised mice.<sup><xref ref-type="bibr" rid="bibr55-1947601912473479">55</xref></sup> This suggests that mutations affecting PP2A/A act by reducing the amount of functional heterotrimers in the cells. More recently, transgenic mice expressing the E64D and E64G mutations and a Δ5-Δ6 mutant with exons 5 and 6 of <italic>PPP2R1A</italic> deleted have been generated.<sup><xref ref-type="bibr" rid="bibr56-1947601912473479">56</xref></sup> PP2A/Aα extracted from the tissues of the E64D and E64G mice was defective in binding the B′ subunit, as previously reported.<sup><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></sup> These mice were around 60% more susceptible to lung tumors than their wild-type counterparts when treated with benzopyrene.<sup><xref ref-type="bibr" rid="bibr56-1947601912473479">56</xref>,<xref ref-type="bibr" rid="bibr57-1947601912473479">57</xref></sup> Together, these studies strongly suggest that the 2 genes (<italic>PPP2R1A</italic> and <italic>PPP2R1B</italic>) encoding PP2A/A scaffolding subunits are haploinsufficient tumor suppressors.</p>
<table-wrap id="table1-1947601912473479" position="float">
<label>Table 1.</label>
<caption>
<p>Alterations in PP2A Subunits in Cancer</p>
</caption>
<graphic alternate-form-of="table1-1947601912473479" xlink:href="10.1177_1947601912473479-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Mutation</th>
<th align="center">Cancer Type</th>
<th align="center">Ref.</th>
<th align="center">Effect on Binding</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">PP2A/Aα</td>
</tr>
<tr>
<td> E64D</td>
<td>Lung</td>
<td><xref ref-type="bibr" rid="bibr51-1947601912473479">51</xref></td>
<td>B’ binding deficient</td>
<td><xref ref-type="bibr" rid="bibr54-1947601912473479">54</xref></td>
</tr>
<tr>
<td> E64G</td>
<td>Breast</td>
<td><xref ref-type="bibr" rid="bibr51-1947601912473479">51</xref></td>
<td>B’ binding deficient</td>
<td><xref ref-type="bibr" rid="bibr54-1947601912473479">54</xref></td>
</tr>
<tr>
<td> R418W</td>
<td>Melanoma</td>
<td><xref ref-type="bibr" rid="bibr51-1947601912473479">51</xref></td>
<td>No B or C binding</td>
<td><xref ref-type="bibr" rid="bibr54-1947601912473479">54</xref></td>
</tr>
<tr>
<td> D171-589</td>
<td>Breast</td>
<td><xref ref-type="bibr" rid="bibr51-1947601912473479">51</xref></td>
<td>No B or C binding</td>
<td><xref ref-type="bibr" rid="bibr54-1947601912473479">54</xref></td>
</tr>
<tr>
<td> P179L</td>
<td>Endometrial</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> R182W</td>
<td>Endometrial</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> S256Y</td>
<td>Endometrial</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> R183Q</td>
<td>Endometrial</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> R249H</td>
<td>Endometrial</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> R182W</td>
<td>Endometrial</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> E216K</td>
<td>Endometrial</td>
<td><xref ref-type="bibr" rid="bibr96-1947601912473479">96</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> R258Y</td>
<td>Endometrial</td>
<td><xref ref-type="bibr" rid="bibr96-1947601912473479">96</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> R258H</td>
<td>Endometrial</td>
<td><xref ref-type="bibr" rid="bibr96-1947601912473479">96</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> R258C</td>
<td>Ovarian</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> W257C</td>
<td>Endometrial, ovarian</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref>, <xref ref-type="bibr" rid="bibr96-1947601912473479">96</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> P179R</td>
<td>Endometrial, ovarian</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> R183W</td>
<td>Endometrial, ovarian</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> S256F</td>
<td>Endometrial, ovarian</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> W257G</td>
<td>Endometrial, ovarian</td>
<td><xref ref-type="bibr" rid="bibr95-1947601912473479">95</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td colspan="5">PP2A/Aβ</td>
</tr>
<tr>
<td> D504G</td>
<td>Lung</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Increased B’’ and C binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> G8R</td>
<td>Lung</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Normal B’’ and C binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> G90D</td>
<td>Lung</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Normal B’’ and C binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> </td>
<td>Breast</td>
<td><xref ref-type="bibr" rid="bibr97-1947601912473479">97</xref></td>
<td>Reduced B’ binding</td>
<td><xref ref-type="bibr" rid="bibr97-1947601912473479">97</xref></td>
</tr>
<tr>
<td> K343E</td>
<td>Lung</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Normal B’’ and C binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> D344-388</td>
<td>Lung</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Reduced B’’ binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> P65S</td>
<td>Lung</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Reduced B’’ binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> L101P</td>
<td>Colon</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Reduced B’’ binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> V545A</td>
<td>Colon</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Reduced B’’ and C binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> V448A</td>
<td>Colon</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Reduced B’’ and C binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> L101P/V448A</td>
<td>Colon</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Reduced B’’ and C binding</td>
<td><xref ref-type="bibr" rid="bibr53-1947601912473479">53</xref></td>
</tr>
<tr>
<td> D230-518</td>
<td>Lung</td>
<td><xref ref-type="bibr" rid="bibr50-1947601912473479">50</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> G15A</td>
<td>Colorectal</td>
<td><xref ref-type="bibr" rid="bibr98-1947601912473479">98</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> S365P</td>
<td>Colorectal</td>
<td><xref ref-type="bibr" rid="bibr98-1947601912473479">98</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> V498E</td>
<td>Colorectal</td>
<td><xref ref-type="bibr" rid="bibr98-1947601912473479">98</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> L499I</td>
<td>Colorectal</td>
<td><xref ref-type="bibr" rid="bibr98-1947601912473479">98</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> V500G</td>
<td>Colorectal</td>
<td><xref ref-type="bibr" rid="bibr98-1947601912473479">98</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td> Deletions</td>
<td>Liver</td>
<td><xref ref-type="bibr" rid="bibr99-1947601912473479">99</xref></td>
<td>Unknown</td>
<td/>
</tr>
<tr>
<td colspan="5">PP2A/B55α</td>
</tr>
<tr>
<td> Deletions</td>
<td>Breast</td>
<td><xref ref-type="bibr" rid="bibr64-1947601912473479">64</xref></td>
<td/>
<td/>
</tr>
<tr>
<td> Deletions</td>
<td>Prostate</td>
<td><xref ref-type="bibr" rid="bibr58-1947601912473479">58</xref></td>
<td/>
<td/>
</tr>
<tr>
<td> Deletions</td>
<td>Ovarian</td>
<td><xref ref-type="bibr" rid="bibr65-1947601912473479">65</xref></td>
<td/>
<td/>
</tr>
<tr>
<td colspan="5">PP2A/B55β</td>
</tr>
<tr>
<td> Hypermethylation</td>
<td>Colorectal</td>
<td><xref ref-type="bibr" rid="bibr66-1947601912473479">66</xref></td>
<td/>
<td/>
</tr>
<tr>
<td> Hypermethylation</td>
<td>Breast</td>
<td><xref ref-type="bibr" rid="bibr67-1947601912473479">67</xref></td>
<td/>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section8-1947601912473479">
<title>Alterations on <italic>PPP2R2A</italic> and <italic>PPP2R2B</italic> in Cancer</title>
<p>Although mutations on the scaffold subunit of PP2A are common in a variety of cancers, mutations in the regulatory subunits of PP2A are rare. Only 4 point mutations in <italic>PPP2R2A</italic>, which encodes the B55α B subunit of PP2A, have been reported in the COSMIC database from 652 sequenced samples, and mutations in other B subunits are uncommon. However, recent studies have shown that deletions of <italic>PPP2R2A</italic>, which maps to chromosome 8p21.2, are extremely common in prostate cancer (PCa) and are also frequent in breast cancer (<xref ref-type="table" rid="table1-1947601912473479">Table 1</xref>). Using Affymetrix 500k/6.0 SNP array analysis of 141 paired normal/cancer prostate samples, investigators found that 84 tumors (59.6%) presented hemizygous deletion of the <italic>PPP2R2A</italic> gene and that 3 tumors (2.1%) had a homozygous deletion. However, there was no apparent correlation between <italic>PPP2R2A</italic> deletion and PCa-specific death, Gleason score, prostate specific antigen levels, or stage. These deletions were all somatic, and no germline deletions were found in 500 nonaggressive and 448 aggressive prostate tumors.<sup><xref ref-type="bibr" rid="bibr58-1947601912473479">58</xref></sup> An independent study conducted to identify recurrent breakpoints in prostate cancer also using the Affymetrix array 6.0 and 500K SNP identified 5 genomic breakpoints in the <italic>PPP2R2A</italic> gene in 78 prostate tumor samples, ranking <italic>PPP2R2A</italic> as the fourth most common genomic breakpoint, ahead of <italic>PTEN, BRCA1</italic>, and <italic>BRCA2</italic>. In addition, qRT-PCR analysis revealed that 8 of 9 paired normal/tumor samples exhibited decreased <italic>PPP2R2A</italic> mRNA expression in the tumors.<sup><xref ref-type="bibr" rid="bibr59-1947601912473479">59</xref></sup> Finally, analysis of the gene copy number alteration (CNA) data from another recent study shows that <italic>PPP2R2A</italic> was homozygously deleted in 7 of 128 (5.5%) and hemizygously deleted in 47 of 128 (36.7%) prostate tumors (Taylor <italic>et al</italic>.,<sup><xref ref-type="bibr" rid="bibr60-1947601912473479">60</xref></sup> supplementary data). Matched mRNA expression Z-scores versus controls showed a correlation with CNA, where median expression values decreased with copy number. Of note, in all these studies the homozygous deletions affecting <italic>PPP2R2A</italic> also eliminate <italic>BNIP3L</italic>, another potential tumor suppressor gene<sup><xref ref-type="bibr" rid="bibr58-1947601912473479">58</xref>,<xref ref-type="bibr" rid="bibr60-1947601912473479">60</xref>,<xref ref-type="bibr" rid="bibr61-1947601912473479">61</xref></sup>; therefore, the contribution of disruption of each of these 2 genes in tumorigenesis remains to be elucidated. Moreover, hemizygous deletions are larger and variable and may affect the expression of other genes. <italic>NKX3.1</italic>, a gene that has been previously implicated in prostate gland development and as a potential haploinsufficient PCa tumor suppressor,<sup><xref ref-type="bibr" rid="bibr62-1947601912473479">62</xref>,<xref ref-type="bibr" rid="bibr63-1947601912473479">63</xref></sup> was found to be homozygously deleted in 4 of 81 prostate tumors (4.9%); however, no co- correlation between mRNA expression and CNA was found, suggesting the alternative presence of other tumor suppressors in this region.<sup><xref ref-type="bibr" rid="bibr60-1947601912473479">60</xref></sup> Importantly, deletion of <italic>PPP2R2A</italic> is not restricted to PCa, as a recently published study of the genomic and transcriptomic architecture of about 2,000 breast tumors has revealed that <italic>PPP2R2A</italic> is 1 of 3 novel deletions that is associated with outlier underexpression of its product. Loss of <italic>PPP2R2A</italic> expression in breast cancer is enriched in mitotic ER-positive cancers (luminal B), allowing for new molecular stratification of breast cancers.<sup><xref ref-type="bibr" rid="bibr64-1947601912473479">64</xref></sup> Moreover, homozygous deletions of <italic>PPP2R2A</italic> are also detected in serous ovarian cancer (4.5%), all indicating that alterations of this gene are not restricted to PCa.<sup><xref ref-type="bibr" rid="bibr65-1947601912473479">65</xref></sup></p>
<p>Promoter silencing via methylation of <italic>PPP2R2B</italic>, which encodes B55β, a regulatory subunit in the same family as B55α, has been found in colorectal cancer (CRC) (<xref ref-type="table" rid="table1-1947601912473479">Table 1</xref>). Downregulation of <italic>PPP2R2B</italic> in CRC-derived patient samples was observed when compared with matched normal colon-derived mucosa in gene expression array analysis, as was hypermethylation of the <italic>PPP2R2B</italic> promoter. Reintroduction of B55β reduced the ability of DLD1 and HCT116 cells to form anchorage-independent colonies in soft agar, and the ability of DLD1 cells to form tumors in nude mice was reduced when B55β was expressed. In this study, it was shown that B55β targets PDK1 to regulate MYC signaling, and in CRC, loss of B55β results in a PDK1-dependent, but PI3K-independent induction of MYC phosphorylation in response to rapamycin, which is reversed upon readdition of B55β.<sup><xref ref-type="bibr" rid="bibr66-1947601912473479">66</xref></sup> Aberrant methylation of <italic>PPP2R2B</italic> has also been detected in ductal carcinoma <italic>in situ</italic> when compared with normal breast tissue.<sup><xref ref-type="bibr" rid="bibr67-1947601912473479">67</xref></sup></p>
<p>Taken together, the observation that PP2A inactivation occurs by different mechanisms affecting distinct trimeric PP2A holoenzymes in different types of cancer strongly suggests that the targets of PP2A inactivation are likely to be specific in subsets of tumors. In other words, the tumor relevant pathways deregulated as result of loss of particular PP2A activities are likely tumor specific.</p>
</sec>
<sec id="section9-1947601912473479">
<title>Alterations on B55α May Be Linked to Inactivation of the Pocket Protein Pathway</title>
<p>The 3 members of the pocket protein family—pRB, p107, and p130—are inactivated by phosphorylation in a cell cycle dependent manner.<sup><xref ref-type="bibr" rid="bibr3-1947601912473479">3</xref>,<xref ref-type="bibr" rid="bibr5-1947601912473479">5</xref>,<xref ref-type="bibr" rid="bibr68-1947601912473479">68</xref>,<xref ref-type="bibr" rid="bibr69-1947601912473479">69</xref></sup> Pocket proteins are hypophosphorylated in quiescent cells or in the G1 phase of the cell cycle preceding the restriction point. Mitogenic stimulation of D-type cyclins′ expression and downregulation and/or sequestration of p27 result in the sequential activation of D-type cyclin/CDK4/6 and cyclin E/CDK2 complexes. These G1/S cyclin/CDK complexes cooperate to hyperphosphorylate and inactivate pocket proteins in mid- to late G1, resulting in disruption of E2F/pocket protein transcriptional repressor complexes and the initiation of a wave of E2F dependent gene transcription required for progression through S phase and mitosis.<sup><xref ref-type="bibr" rid="bibr69-1947601912473479">69</xref>,<xref ref-type="bibr" rid="bibr70-1947601912473479">70</xref></sup> Pocket proteins remain hyperphosphorylated through S, G2, and most M phase, as other cyclin/ CDK complexes are active through these phases. Coinciding with CDK inactivation in mitosis, pocket proteins are abruptly dephosphorylated and reset to their active state, as cells exit mitosis and enter the next G1 phase. The finding that protein phosphatase 1 (PP1) associates with pRB in late mitosis and early G1 and subsequent studies led to a model in which pocket proteins were switched off by inducible CDKs from mid- to late G1 though the point in mitosis where CDKs were inactivated, which in turn was associated with activation of PP1 and the reactivation of pocket proteins.<sup><xref ref-type="bibr" rid="bibr71-1947601912473479">71</xref><xref ref-type="bibr" rid="bibr72-1947601912473479"/>-<xref ref-type="bibr" rid="bibr73-1947601912473479">73</xref></sup> However, our laboratory found that treatment of exponentially growing cells with small pharmacological compounds that rapidly inhibit expression of D-type cyclin or CDK activity resulted in immediate dephosphorylation of pocket proteins.<sup><xref ref-type="bibr" rid="bibr74-1947601912473479">74</xref></sup> This dephosphorylation could be mediated by a phosphatase that is constitutively active throughout the cell cycle or, alternatively, the recruitment of a phosphatase to pocket proteins following CDK inhibition. This dephosphorylation could be prevented pharmacologically with concentrations of OA that inhibit PP2A but not PP1 and via expression of SV40 st, implicating PP2A as the phosphatase responsible. In agreement with these results, PP2A/C was found to co-immunoprecipitate with p107 and p130 in both quiescent and exponentially growing cells. Altogether this suggested that a heterotrimeric PP2A holoenzyme(s) acts in a dynamic equilibrium with inducible CDKs to maintain the phosphorylation state of pocket proteins through the cell cycle and in quiescent cells<sup><xref ref-type="bibr" rid="bibr74-1947601912473479">74</xref></sup> (<xref ref-type="fig" rid="fig2-1947601912473479">Figure 2</xref>). The data also showed that reduction of particular cyclin/CDK activities had an intermediate effect, which could be explained by a shift in the PP2A/CDK equilibrium or by dephosphorylation of sites specific to the cyclin/CDK complexes being downregulated.<sup><xref ref-type="bibr" rid="bibr74-1947601912473479">74</xref></sup> The notion that the phosphorylation state of pRB could be determined by the ratio of pRB kinases and phosphatases has also been proposed.<sup><xref ref-type="bibr" rid="bibr75-1947601912473479">75</xref></sup></p>
<fig id="fig2-1947601912473479" position="float">
<label>Figure 2.</label>
<caption>
<p>The phosphorylation state of pocket proteins is regulated by an equilibrium between inducible cyclin/CDK complexes and 2 major types of Ser/Thr phosphatases. The active, hypophosphorylated form of pocket proteins is shown in green, and the inactive, hyperphosphorylated pocket protein is shown in red. Although PP1 has been implicated in dephosphorylation of pRB from late mitosis to G1, when CDK activity is low, PP2A appears to restrict pocket protein phosphorylation throughout the cell cycle and in quiescent cells (not shown in this figure). Two heterotrimeric complexes have been directly implicated in dephosphorylation of pocket proteins, PP2A/B55α and PP2A/PR70. PP2A/B55α was shown to preferentially target p107 and p130, but our unpublished observations indicate that pRB is also a target. PP2A/PR70 has been implicated in pRB dephosphorylation upon oxidative stress. However, its contribution to the phosphorylation state of pocket proteins in the absence of inducible signals has not been investigated. The approximate portion of the cell cycle in which each participating CDK and Ser/Thr phosphatase is active toward pocket proteins is indicated by dashed lines. Of note, the expression of D-type cyclins during the cell cycle, which is stimulated by mitogens, varies in different cell types. In some cell types, D-type cyclins are only expressed from mid-G1 through the G1/S transition (this is denoted by dashes changing to dots).</p>
</caption>
<graphic xlink:href="10.1177_1947601912473479-fig2.tif"/>
</fig>
<p>More recently, it has been shown that PP2A/PR70 holoenzymes target pRB for dephosphorylation upon oxidative stress,<sup><xref ref-type="bibr" rid="bibr76-1947601912473479">76</xref></sup> and our laboratory identified PP2A/B55α holoenzymes as being responsible for the dephosphorylation of p107 and, likely, p130.<sup><xref ref-type="bibr" rid="bibr23-1947601912473479">23</xref></sup> Of note, expression of SV40 st in cells dissociated the PP2A/A-C core dimer from B55α, but p107 remained bound to B55α. In agreement with this result, we also found that a B55α point mutant (D197K), which lacks a residue in a surface predicted to interact with substrates,<sup><xref ref-type="bibr" rid="bibr77-1947601912473479">77</xref></sup> was unable to interact with p107 yet retained, albeit reduced, an interaction with the PP2A/ A-C core dimer.<sup><xref ref-type="bibr" rid="bibr23-1947601912473479">23</xref></sup> Strikingly, both loss and gain of function assays suggested that the steady state phosphorylation of p107 is highly sensitive to variations in B55α expression in a variety of cells tested thus far, suggesting that regulation of B55α activity in cells is likely to have an impact on the activation state of pocket proteins. Obviously, this has implications in cancer, as genetic/epigenetic alterations leading to downregulation of pocket protein phosphatases could function as an alternative mechanism to inactivate the pRB pathway (<xref ref-type="fig" rid="fig3-1947601912473479">Figure 3</xref>). One conceivable example is downregulation of B55α as a result of deletions on chromosome 8p21 that eliminated <italic>PPP2R2A</italic> in a variety of cancers, but most prominently in PCa.<sup><xref ref-type="bibr" rid="bibr58-1947601912473479">58</xref>,<xref ref-type="bibr" rid="bibr60-1947601912473479">60</xref></sup> More work is needed to test this idea.</p>
<fig id="fig3-1947601912473479" position="float">
<label>Figure 3.</label>
<caption>
<p>The pocket protein regulatory network is disrupted by multiple mechanisms in cancer. Tumor suppressors in the network are inactivated via point mutations or deletions (X) or via epigenetic silencing or increased proteolytic degradation (↓). Mutations and or deletions affecting pRB, p130, and p16 have been described (reviewed in Malumbres &amp; Barbacid<sup><xref ref-type="bibr" rid="bibr94-1947601912473479">94</xref></sup>). Amplification of cyclins or defects in their degradation pathways is also common (↑). The pathway can be disrupted by a mutation on CDK4 that makes it resistant to CDK inhibitors (X). Deletions affecting expression of B55α have been described in a variety of cancers (see text) and may affect this equilibrium.</p>
</caption>
<graphic xlink:href="10.1177_1947601912473479-fig3.tif"/>
</fig>
</sec>
<sec id="section10-1947601912473479">
<title>Alterations on <italic>PPP2R2A</italic> May Be Linked to Mitotic Defects</title>
<p>PP2A/B55 complexes play a critical role in promoting mitotic exit in higher eukaryotes by dephosphorylating many substrates phosphorylated by CDK1 in mitosis.<sup><xref ref-type="bibr" rid="bibr78-1947601912473479">78</xref></sup> Of note, as opposed to the universal involvement of CDK1 in triggering mitotic events in all eukaryotes, dephosphorylation of CDK1 substrates seems to be accomplished by different phosphatases in yeast and animal cells. An RNAi-based live-cell imaging screen identified B55α and the nuclear transport factor importin-β as key regulators in postmitotic spindle breakdown, nuclear envelop reassembly, chromatin decondensation, and Golgi assembly.<sup><xref ref-type="bibr" rid="bibr79-1947601912473479">79</xref></sup> In this study, mass spectrometry was used to identify regulated phosphorylation sites of the subunits of the heterotrimeric complex. Phosphorylation on Ser 167 of the B55α subunit was by far the most abundant and was enriched more than 5-fold in mitotic cells.<sup><xref ref-type="bibr" rid="bibr79-1947601912473479">79</xref></sup> Consistently, a B55α phosphorylation mimic mutant bound the PP2AC A-C dimer less efficiently than wild-type B55α in <italic>in vitro</italic> pulldown assays. Although these results suggested that the heterotrimeric PP2A/B55α complex may be negatively regulated via phosphorylation, further work is needed to clarify the kinetics of phosphorylation, its effects on the holoenzyme activity, and the upstream regulators.</p>
<p>Previous studies showed that <italic>Drosophila</italic> B55 mutants with reduced activity exhibited mitotic defects and reduced ability to dephosphorylate CDK1 substrates <italic>in vitro</italic>.<sup><xref ref-type="bibr" rid="bibr80-1947601912473479">80</xref></sup> In <italic>Xenopus</italic> extracts, PP2A/B55δ holoenzymes also appear to be responsible for dephosphorylation of many CDK substrates in interphase, and their activity is negatively regulated by the Greatwall (GW) kinase in mitosis, which is activated by CDK1. In the absence of GW, <italic>Xenopus</italic> extracts cannot enter M phase, but this is corrected by depletion of B55δ,<sup><xref ref-type="bibr" rid="bibr81-1947601912473479">81</xref></sup> and GW depletion promotes mitotic exit even with high CDK1 activity.<sup><xref ref-type="bibr" rid="bibr82-1947601912473479">82</xref></sup> Conversely, depletion of B55δ accelerates entry into mitosis.<sup><xref ref-type="bibr" rid="bibr83-1947601912473479">83</xref></sup> Two substrates of GW, ENSA and ARPP19, have been identified as novel inhibitors of PP2A during mitosis. In one study, ENSA and ARPP19 were both shown to bind PP2A; however, only ARPP19 was required to promote mitotic entry in Xenopus egg extracts.<sup><xref ref-type="bibr" rid="bibr84-1947601912473479">84</xref></sup> In another study, it was shown that phosphorylated ENSA specifically targets and inhibits PP2A/B55δ holoenzymes in <italic>Xenopus</italic>, ultimately leading to CDK1 activation.<sup><xref ref-type="bibr" rid="bibr85-1947601912473479">85</xref></sup> Moreover, in mammals GW is designated MASTL (MASTL/GW), and at least 2 B55 subunits, B55α (mentioned above) and B55δ, appear to work downstream. In MEFs, targeted inactivation of CDC20, the activating subunit of the anaphase promoting complex (APC), results in metaphase arrest. In these cells, mitotic exit can be induced by pharmacological inhibition of both CDK1 (with Roscovitine) and MASTL/GW (siRNA). Under these conditions, depletion of B55α and/or B55δ with specific siRNAs blocks mitotic exit.<sup><xref ref-type="bibr" rid="bibr86-1947601912473479">86</xref></sup> Thus, the requirement of members of the B55 family of heterotrimeric complexes for mitotic exit and their negative regulation by MASTL/GW is conserved in vertebrates. Of note, B55β and B55γ are not expressed at high levels in MEFs, as their expression is tissue specific, so it is conceivable that they would play a similar role in those cell types were they are expressed at significant levels.</p>
<p>In closing, the critical importance of B55α in mitotic exit, so far analyzed in HeLa cells and MEFs, also has implications in cancer given the high frequency of deletions affecting <italic>PPP2R2A</italic>, at least in prostate, ovarian and breast cancer. Hemizygous deletions on <italic>PPP2R2A</italic> may result in limiting levels of B55α for effective mitotic exit, which may facilitate mitotic defects and potentially genetic instability. However, the role of B55α in modulating the activation state of p107/p130 and perhaps also pRB suggests that elimination of <italic>PPP2R2A</italic> may be pleiotropic, especially if one also considers that B55α has been implicated in the negative regulation of mitogenic and survival pathways. The consequences of B55α deregulation will most likely vary in a cell type specific manner, reflecting the relative importance of this B regulatory subunit in each cell type.</p>
<p>In contrast, the high frequency of hemizygous deletions affecting the <italic>PPP2R2A</italic> locus, without alteration in the other allele, provides a potential strategy for therapeutics using small pharmacologic molecules with the ability to boost the activity of the product of the remaining intact allele. This idea has been tested in preclinical studies in leukemia where PP2A activity is reduced by deregulated endogenous inhibitors of PP2A (see sections above). FTY720 is a pharmacological activator of PP2A, which the FDA approved for use in the treatment of multiple sclerosis in humans, and is well tolerated.<sup><xref ref-type="bibr" rid="bibr57-1947601912473479">57</xref>,<xref ref-type="bibr" rid="bibr87-1947601912473479">87</xref><xref ref-type="bibr" rid="bibr88-1947601912473479"/>-<xref ref-type="bibr" rid="bibr89-1947601912473479">89</xref></sup> FTY720 has been shown to have antitumoral activity in mouse xenografts of human tumors with no toxicity to mice. In addition to the established effect of FTY720 on leukemias, it has been shown that prostate cancer cell lines are more sensitive to FTY720 than prostate stromal cells.<sup><xref ref-type="bibr" rid="bibr90-1947601912473479">90</xref></sup> FTY720 also induced cytoskeletal changes in murine breast cancer cells and decreased their ability to adhere and migrate to extracellular matrix components,<sup><xref ref-type="bibr" rid="bibr91-1947601912473479">91</xref></sup> and it inhibited metastasis of hepatocellular carcinoma cells in nude mice via inhibition of Rac-mediated cell motility and VEGF-mediated angiogenesis.<sup><xref ref-type="bibr" rid="bibr92-1947601912473479">92</xref></sup> Because FTY720 is known to activate PP2A enzymatic activity independently of trimeric holoenzyme composition,<sup><xref ref-type="bibr" rid="bibr93-1947601912473479">93</xref></sup> it is conceivable that it might also alleviate the effects of reduction on B55α holoenzymes in mitosis and/or the activation of pocket proteins. Future studies should address these issues.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Work in the XG laboratory was supported by the National Institutes of Health Grant MH083585 and by a grant from the Pennsylvania Department of Health to X.G.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1947601912473479">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shi</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Serine/threonine phosphatases: mechanism through structure</article-title>. <source>Cell</source> <year>2009</year>;<volume>139</volume>:<fpage>468</fpage>-<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr2-1947601912473479">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Virshup</surname><given-names>DM</given-names></name>
<name><surname>Shenolikar</surname><given-names>S</given-names></name>
</person-group>. <article-title>From promiscuity to precision: protein phosphatases get a makeover</article-title>. <source>Mol Cell</source>. <year>2009</year>;<volume>33</volume>:<fpage>537</fpage>-<lpage>545</lpage>.</citation>
</ref>
<ref id="bibr3-1947601912473479">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurimchak</surname><given-names>A</given-names></name>
<name><surname>Graña</surname><given-names>X</given-names></name>
</person-group>. <article-title>PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates</article-title>. <source>Gene</source>. <year>2012</year>;<volume>499</volume>:<fpage>1</fpage>-<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr4-1947601912473479">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eichhorn</surname><given-names>PJ</given-names></name>
<name><surname>Creyghton</surname><given-names>MP</given-names></name>
<name><surname>Bernards</surname><given-names>R</given-names></name>
</person-group>. <article-title>Protein phosphatase 2A regulatory subunits and cancer</article-title>. <source>Biochim Biophys Acta</source>. <year>2009</year>;<volume>1795</volume>:<fpage>1</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr5-1947601912473479">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kolupaeva</surname><given-names>V</given-names></name>
<name><surname>Janssens</surname><given-names>V</given-names></name>
</person-group>. <article-title>PP1 and PP2A phosphatases—cooperating partners in modulating retinoblastoma protein activation</article-title>. <source>FEBS J</source>. Epub <year>2012</year> <month>Feb</month> <day>2</day>.</citation>
</ref>
<ref id="bibr6-1947601912473479">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>P</given-names></name>
<name><surname>Holmes</surname><given-names>CF</given-names></name>
<name><surname>Tsukitani</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Okadaic acid: a new probe for the study of cellular regulation</article-title>. <source>Trends Biochem Sci</source>. <year>1990</year>;<volume>15</volume>:<fpage>98</fpage>-<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr7-1947601912473479">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bialojan</surname><given-names>C</given-names></name>
<name><surname>Takai</surname><given-names>A</given-names></name>
</person-group>. <article-title>Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases:xpecificity and kinetics</article-title>. <source>Biochem J</source>. <year>1988</year>;<volume>256</volume>:<fpage>283</fpage>-<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr8-1947601912473479">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fujiki</surname><given-names>H</given-names></name>
<name><surname>Suganuma</surname><given-names>M</given-names></name>
<name><surname>Suguri</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Induction of ornithine decarboxylase activity in mouse skin by a possible tumor promoter, okadaic acid</article-title>. <source>Proc Jpn Acad Ser B Phys Biol Sci</source>. <year>1987</year>;<volume>63</volume>:<fpage>51</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr9-1947601912473479">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suganuma</surname><given-names>M</given-names></name>
<name><surname>Fujiki</surname><given-names>H</given-names></name>
<name><surname>Suguri</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1988</year>;<volume>85</volume>:<fpage>1768</fpage>-<lpage>1771</lpage>.</citation>
</ref>
<ref id="bibr10-1947601912473479">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suganuma</surname><given-names>M</given-names></name>
<name><surname>Fujiki</surname><given-names>H</given-names></name>
<name><surname>Furuya-Suguri</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Calyculin A, an inhibitor of protein phosphatases, a potent tumor promoter on CD-1 mouse skin</article-title>. <source>Cancer Res</source>. <year>1990</year>;<volume>50</volume>:<fpage>3521</fpage>-<lpage>3525</lpage>.</citation>
</ref>
<ref id="bibr11-1947601912473479">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ishihara</surname><given-names>H</given-names></name>
<name><surname>Martin</surname><given-names>B. L</given-names></name>
<name><surname>Brautigan</surname><given-names>DL</given-names></name>
<etal/>
</person-group>. <article-title>Calyculin A and okadaic acid: inhibitors of protein phosphatase activity</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1989</year>;<volume>159</volume>:<fpage>871</fpage>-<lpage>877</lpage>.</citation>
</ref>
<ref id="bibr12-1947601912473479">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suganuma</surname><given-names>M</given-names></name>
<name><surname>Fujiki</surname><given-names>H</given-names></name>
<name><surname>Okabe</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Structurally different members of the okadaic acid class selectively inhibit protein serine/threonine but not tyrosine phosphatase activity</article-title>. <source>Toxicon</source>. <year>1992</year>;<volume>30</volume>:<fpage>873</fpage>-<lpage>878</lpage>.</citation>
</ref>
<ref id="bibr13-1947601912473479">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ali</surname><given-names>SH</given-names></name>
<name><surname>DeCaprio</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Cellular transformation by SV40 large T antigen: interaction with host proteins</article-title>. <source>Semin Cancer Biol</source>. <year>2001</year>;<volume>11</volume>:<fpage>15</fpage>-<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr14-1947601912473479">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pallas</surname><given-names>DC</given-names></name>
<name><surname>Cherington</surname><given-names>V</given-names></name>
<name><surname>Morgan</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Cellular proteins that associate with the middle and small T antigens of polyomavirus</article-title>. <source>J Virol</source>. <year>1988</year>;<volume>62</volume>:<fpage>3934</fpage>-<lpage>3940</lpage>.</citation>
</ref>
<ref id="bibr15-1947601912473479">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walter</surname><given-names>G</given-names></name>
<name><surname>Carbone-Wiley</surname><given-names>A</given-names></name>
<name><surname>Joshi</surname><given-names>B</given-names></name>
<name><surname>Rundell</surname><given-names>K</given-names></name>
</person-group>. <article-title>Homologous cellular proteins associated with simian virus 40 small T antigen and polyomavirus medium T antigen</article-title>. <source>J Virol</source>. <year>1988</year>;<volume>62</volume>:<fpage>4760</fpage>-<lpage>4762</lpage>.</citation>
</ref>
<ref id="bibr16-1947601912473479">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>YC</given-names></name>
<name><surname>Hearing</surname><given-names>P</given-names></name>
<name><surname>Rundell</surname><given-names>K</given-names></name>
</person-group>. <article-title>Cellular proteins associated with simian virus 40 early gene products in newly infected cells</article-title>. <source>J Virol</source>. <year>1979</year>;<volume>32</volume>:<fpage>147</fpage>-<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr17-1947601912473479">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grussenmeyer</surname><given-names>T</given-names></name>
<name><surname>Scheidtmann</surname><given-names>KH</given-names></name>
<name><surname>Hutchinson</surname><given-names>MA</given-names></name>
<name><surname>Eckhart</surname><given-names>W</given-names></name>
<name><surname>Walter</surname><given-names>G</given-names></name>
</person-group>. <article-title>Complexes of polyoma virus medium T antigen and cellular proteins</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1985</year>;<volume>82</volume>:<fpage>7952</fpage>-<lpage>7954</lpage>.</citation>
</ref>
<ref id="bibr18-1947601912473479">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pallas</surname><given-names>DC</given-names></name>
<name><surname>Shahrik</surname><given-names>LK</given-names></name>
<name><surname>Martin</surname><given-names>BL</given-names></name>
<etal/>
</person-group>. <article-title>Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A</article-title>. <source>Cell</source>. <year>1990</year>;<volume>60</volume>:<fpage>167</fpage>-<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr19-1947601912473479">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walter</surname><given-names>G</given-names></name>
<name><surname>Ruediger</surname><given-names>R</given-names></name>
<name><surname>Slaughter</surname><given-names>C</given-names></name>
<name><surname>Mumby</surname><given-names>M</given-names></name>
</person-group>. <article-title>Association of protein phosphatase 2A with polyoma virus medium tumor antigen</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1990</year>;<volume>87</volume>:<fpage>2521</fpage>-<lpage>2525</lpage>.</citation>
</ref>
<ref id="bibr20-1947601912473479">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arroyo</surname><given-names>JD</given-names></name>
<name><surname>Hahn</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Involvement of PP2A in viral and cellular transformation</article-title>. <source>Oncogene</source>. <year>2005</year>;<volume>24</volume>:<fpage>7746</fpage>-<lpage>7755</lpage>.</citation>
</ref>
<ref id="bibr21-1947601912473479">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sontag</surname><given-names>E</given-names></name>
<name><surname>Fedorov</surname><given-names>S</given-names></name>
<name><surname>Kamibayashi</surname><given-names>C</given-names></name>
<name><surname>Robbins</surname><given-names>D</given-names></name>
<name><surname>Cobb</surname><given-names>M</given-names></name>
<name><surname>Mumby</surname><given-names>M</given-names></name>
</person-group>. <article-title>The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation</article-title>. <source>Cell</source>. <year>1993</year>;<volume>75</volume>:<fpage>887</fpage>-<lpage>897</lpage>.</citation>
</ref>
<ref id="bibr22-1947601912473479">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W</given-names></name>
<name><surname>Possemato</surname><given-names>R</given-names></name>
<name><surname>Campbell</surname><given-names>KT</given-names></name>
<name><surname>Plattner</surname><given-names>CA</given-names></name>
<name><surname>Pallas</surname><given-names>DC</given-names></name>
<name><surname>Hahn</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Identification of specific PP2A complexes involved in human cell transformation</article-title>. <source>Cancer Cell</source>. <year>2004</year>;<volume>5</volume>:<fpage>127</fpage>-<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr23-1947601912473479">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jayadeva</surname><given-names>G</given-names></name>
<name><surname>Kurimchak</surname><given-names>A</given-names></name>
<name><surname>Garriga</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>B55alpha PP2A holoenzymes modulate the phosphorylation status of the retinoblastoma-related protein p107 and its activation</article-title>. <source>J Biol Chem</source>. <year>2010</year>;<volume>285</volume>:<fpage>29863</fpage>-<lpage>29873</lpage>.</citation>
</ref>
<ref id="bibr24-1947601912473479">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>SI</given-names></name>
<name><surname>Lickteig</surname><given-names>RL</given-names></name>
<name><surname>Estes</surname><given-names>R</given-names></name>
<name><surname>Rundell</surname><given-names>K</given-names></name>
<name><surname>Walter</surname><given-names>G</given-names></name>
<name><surname>Mumby</surname><given-names>MC</given-names></name>
</person-group>. <article-title>Control of protein phosphatase 2A by simian virus 40 small-t antigen</article-title>. <source>Mol Cell Biol</source>. <year>1991</year>;<volume>11</volume>:<fpage>1988</fpage>-<lpage>1995</lpage>.</citation>
</ref>
<ref id="bibr25-1947601912473479">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cho</surname><given-names>US</given-names></name>
<name><surname>Morrone</surname><given-names>S</given-names></name>
<name><surname>Sablina</surname><given-names>AA</given-names></name>
<name><surname>Arroyo</surname><given-names>JD</given-names></name>
<name><surname>Hahn</surname><given-names>WC</given-names></name>
<name><surname>Xu</surname><given-names>W</given-names></name>
</person-group>. <article-title>Structural basis of PP2A inhibition by small t antigen</article-title>. <source>PLoS Biol</source>. <year>2007</year>;<volume>5</volume>:<fpage>e202</fpage>.</citation>
</ref>
<ref id="bibr26-1947601912473479">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Bao</surname><given-names>Q</given-names></name>
<etal/>
</person-group>. <article-title>Structural and biochemical insights into the regulation of protein phosphatase 2A by small t antigen of SV40</article-title>. <source>Nat Struct Mol Biol</source>. <year>2007</year>;<volume>14</volume>:<fpage>527</fpage>-<lpage>534</lpage>.</citation>
</ref>
<ref id="bibr27-1947601912473479">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>WC</given-names></name>
<name><surname>Counter</surname><given-names>CM</given-names></name>
<name><surname>Lundberg</surname><given-names>AS</given-names></name>
<name><surname>Beijersbergen</surname><given-names>RL</given-names></name>
<name><surname>Brooks</surname><given-names>MW</given-names></name>
<name><surname>Weinberg</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Creation of human tumour cells with defined genetic elements</article-title>. <source>Nature</source>. <year>1999</year>;<volume>400</volume>:<fpage>464</fpage>-<lpage>468</lpage>.</citation>
</ref>
<ref id="bibr28-1947601912473479">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W</given-names></name>
<name><surname>Hahn</surname><given-names>WC</given-names></name>
</person-group>. <article-title>SV40 early region oncoproteins and human cell transformation</article-title>. <source>Histol Histopathol</source>. <year>2003</year>;<volume>18</volume>:<fpage>541</fpage>-<lpage>550</lpage>.</citation>
</ref>
<ref id="bibr29-1947601912473479">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>WC</given-names></name>
<name><surname>Dessain</surname><given-names>SK</given-names></name>
<name><surname>Brooks</surname><given-names>MW</given-names></name>
<etal/>
</person-group>. <article-title>Enumeration of the simian virus 40 early region elements necessary for human cell transformation</article-title>. <source>Mol Cell Biol</source>. <year>2002</year>;<volume>22</volume>:<fpage>2111</fpage>-<lpage>2123</lpage>.</citation>
</ref>
<ref id="bibr30-1947601912473479">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sablina</surname><given-names>AA</given-names></name>
<name><surname>Hector</surname><given-names>M</given-names></name>
<name><surname>Colpaert</surname><given-names>N</given-names></name>
<name><surname>Hahn</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Identification of PP2A complexes and pathways involved in cell transformation</article-title>. <source>Cancer Res</source>. <year>2010</year>;<volume>70</volume>:<fpage>10474</fpage>-<lpage>10484</lpage>.</citation>
</ref>
<ref id="bibr31-1947601912473479">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kleinberger</surname><given-names>T</given-names></name>
<name><surname>Shenk</surname><given-names>T</given-names></name>
</person-group>. <article-title>Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription</article-title>. <source>J Virol</source>. <year>1993</year>;<volume>67</volume>:<fpage>7556</fpage>-<lpage>7560</lpage>.</citation>
</ref>
<ref id="bibr32-1947601912473479">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shtrichman</surname><given-names>R</given-names></name>
<name><surname>Sharf</surname><given-names>R</given-names></name>
<name><surname>Barr</surname><given-names>H</given-names></name>
<name><surname>Dobner</surname><given-names>T</given-names></name>
<name><surname>Kleinberger</surname><given-names>T</given-names></name>
</person-group>. <article-title>Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1999</year>;<volume>96</volume>:<fpage>10080</fpage>-<lpage>10085</lpage>.</citation>
</ref>
<ref id="bibr33-1947601912473479">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shtrichman</surname><given-names>R</given-names></name>
<name><surname>Sharf</surname><given-names>R</given-names></name>
<name><surname>Kleinberger</surname><given-names>T</given-names></name>
</person-group>. <article-title>Adenovirus E4orf4 protein interacts with both Balpha and B′ subunits of protein phosphatase 2A, but E4orf4-induced apoptosis is mediated only by the interaction with Balpha</article-title>. <source>Oncogene</source>. <year>2000</year>;<volume>19</volume>:<fpage>3757</fpage>-<lpage>3765</lpage>.</citation>
</ref>
<ref id="bibr34-1947601912473479">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Hoof</surname><given-names>C</given-names></name>
<name><surname>Goris</surname><given-names>J</given-names></name>
</person-group>. <article-title>Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question</article-title>. <source>Biochim Biophys Acta</source>. <year>2003</year>;<volume>1640</volume>:<fpage>97</fpage>-<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr35-1947601912473479">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marcellus</surname><given-names>RC</given-names></name>
<name><surname>Chan</surname><given-names>H</given-names></name>
<name><surname>Paquette</surname><given-names>D</given-names></name>
<name><surname>Thirlwell</surname><given-names>S</given-names></name>
<name><surname>Boivin</surname><given-names>D</given-names></name>
<name><surname>Branton</surname><given-names>PE</given-names></name>
</person-group>. <article-title>Induction of p53-independent apoptosis by the adenovirus E4orf4 protein requires binding to the Balpha subunit of protein phosphatase 2A</article-title>. <source>J Virol</source>. <year>2000</year>;<volume>74</volume>:<fpage>7869</fpage>-<lpage>7877</lpage>.</citation>
</ref>
<ref id="bibr36-1947601912473479">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ben-Israel</surname><given-names>H</given-names></name>
<name><surname>Sharf</surname><given-names>R</given-names></name>
<name><surname>Rechavi</surname><given-names>G</given-names></name>
<name><surname>Kleinberger</surname><given-names>T</given-names></name>
</person-group>. <article-title>Adenovirus E4orf4 protein downregulates MYC expression through interaction with the PP2A-B55 subunit</article-title>. <source>J Virol</source>. <year>2008</year>;<volume>82</volume>:<fpage>9381</fpage>-<lpage>9388</lpage>.</citation>
</ref>
<ref id="bibr37-1947601912473479">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>S</given-names></name>
<name><surname>Brignole</surname><given-names>C</given-names></name>
<name><surname>Marcellus</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>The adenovirus E4orf4 protein induces G2/M arrest and cell death by blocking protein phosphatase 2A activity regulated by the B55 subunit</article-title>. <source>J Virol</source>. <year>2009</year>;<volume>83</volume>:<fpage>8340</fpage>-<lpage>8352</lpage>.</citation>
</ref>
<ref id="bibr38-1947601912473479">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Branton</surname><given-names>PE</given-names></name>
<name><surname>Roopchand</surname><given-names>DE</given-names></name>
</person-group>. <article-title>The role of adenovirus E4orf4 protein in viral replication and cell killing</article-title>. <source>Oncogene</source>. <year>2001</year>;<volume>20</volume>:<fpage>7855</fpage>-<lpage>7865</lpage>.</citation>
</ref>
<ref id="bibr39-1947601912473479">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soo Hoo</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>JY</given-names></name>
<name><surname>Chan</surname><given-names>EK</given-names></name>
</person-group>. <article-title>Cloning and characterization of a novel 90 kDa “companion” auto-antigen of p62 overexpressed in cancer</article-title>. <source>Oncogene</source>. <year>2002</year>;<volume>21</volume>:<fpage>5006</fpage>-<lpage>5015</lpage>.</citation>
</ref>
<ref id="bibr40-1947601912473479">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yeh</surname><given-names>E</given-names></name>
<name><surname>Cunningham</surname><given-names>M</given-names></name>
<name><surname>Arnold</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells</article-title>. <source>Nat Cell Biol</source>. <year>2004</year>;<volume>6</volume>:<fpage>308</fpage>-<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr41-1947601912473479">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>HK</given-names></name>
<name><surname>Sears</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation</article-title>. <source>Mol Cell Biol</source>. <year>2006</year>;<volume>26</volume>:<fpage>2832</fpage>-<lpage>2844</lpage>.</citation>
</ref>
<ref id="bibr42-1947601912473479">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Junttila</surname><given-names>MR</given-names></name>
<name><surname>Puustinen</surname><given-names>P</given-names></name>
<name><surname>Niemela</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>CIP2A inhibits PP2A in human malignancies</article-title>. <source>Cell</source>. <year>2007</year>;<volume>130</volume>:<fpage>51</fpage>-<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr43-1947601912473479">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khanna</surname><given-names>A</given-names></name>
<name><surname>Bockelman</surname><given-names>C</given-names></name>
<name><surname>Hemmes</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>MYC-dependent regulation and prognostic role of CIP2A in gastric cancer</article-title>. <source>J Natl Cancer Inst</source>. <year>2009</year>;<volume>101</volume>:<fpage>793</fpage>-<lpage>805</lpage>.</citation>
</ref>
<ref id="bibr44-1947601912473479">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Westermarck</surname><given-names>J</given-names></name>
<name><surname>Hahn</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Multiple pathways regulated by the tumor suppressor PP2A in transformation</article-title>. <source>Trends Mol Med</source>. <year>2008</year>;<volume>14</volume>:<fpage>152</fpage>-<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr45-1947601912473479">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Come</surname><given-names>C</given-names></name>
<name><surname>Laine</surname><given-names>A</given-names></name>
<name><surname>Chanrion</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>CIP2A is associated with human breast cancer aggressivity</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>:<fpage>5092</fpage>-<lpage>5100</lpage>.</citation>
</ref>
<ref id="bibr46-1947601912473479">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>Guo</surname><given-names>H</given-names></name>
<name><surname>Damuni</surname><given-names>Z</given-names></name>
</person-group>. <article-title>Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney</article-title>. <source>Biochemistry</source>. <year>1995</year>;<volume>34</volume>:<fpage>1988</fpage>-<lpage>1996</lpage>.</citation>
</ref>
<ref id="bibr47-1947601912473479">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>Makkinje</surname><given-names>A</given-names></name>
<name><surname>Damuni</surname><given-names>Z</given-names></name>
</person-group>. <article-title>The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A</article-title>. <source>J Biol Chem</source>. <year>1996</year>;<volume>271</volume>:<fpage>11059</fpage>-<lpage>11062</lpage>.</citation>
</ref>
<ref id="bibr48-1947601912473479">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>von Lindern</surname><given-names>M</given-names></name>
<name><surname>van Baal</surname><given-names>S</given-names></name>
<name><surname>Wiegant</surname><given-names>J</given-names></name>
<name><surname>Raap</surname><given-names>A</given-names></name>
<name><surname>Hagemeijer</surname><given-names>A</given-names></name>
<name><surname>Grosveld</surname><given-names>G</given-names></name>
</person-group>. <article-title>Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene</article-title>. <source>Mol Cell Biol</source>. <year>1992</year>;<volume>12</volume>:<fpage>3346</fpage>-<lpage>3355</lpage>.</citation>
</ref>
<ref id="bibr49-1947601912473479">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neviani</surname><given-names>P</given-names></name>
<name><surname>Santhanam</surname><given-names>R</given-names></name>
<name><surname>Trotta</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein</article-title>. <source>Cancer Cell</source>. <year>2005</year>;<volume>8</volume>:<fpage>355</fpage>-<lpage>368</lpage>.</citation>
</ref>
<ref id="bibr50-1947601912473479">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>SS</given-names></name>
<name><surname>Esplin</surname><given-names>ED</given-names></name>
<name><surname>Li</surname><given-names>JL</given-names></name>
<etal/>
</person-group>. <article-title>Alterations of the PPP2R1B gene in human lung and colon cancer</article-title>. <source>Science</source>. <year>1998</year>;<volume>282</volume>:<fpage>284</fpage>-<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr51-1947601912473479">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calin</surname><given-names>GA</given-names></name>
<name><surname>di Iasio</surname><given-names>MG</given-names></name>
<name><surname>Caprini</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms</article-title>. <source>Oncogene</source>. <year>2000</year>;<volume>19</volume>:<fpage>1191</fpage>-<lpage>1195</lpage>.</citation>
</ref>
<ref id="bibr52-1947601912473479">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruediger</surname><given-names>R</given-names></name>
<name><surname>Hentz</surname><given-names>M</given-names></name>
<name><surname>Fait</surname><given-names>J</given-names></name>
<name><surname>Mumby</surname><given-names>M</given-names></name>
<name><surname>Walter</surname><given-names>G</given-names></name>
</person-group>. <article-title>Molecular model of the A subunit of protein phosphatase 2A: interaction with other subunits and tumor antigens</article-title>. <source>J Virol</source>. <year>1994</year>;<volume>68</volume>:<fpage>123</fpage>-<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr53-1947601912473479">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruediger</surname><given-names>R</given-names></name>
<name><surname>Pham</surname><given-names>HT</given-names></name>
<name><surname>Walter</surname><given-names>G</given-names></name>
</person-group>. <article-title>Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene</article-title>. <source>Oncogene</source>. <year>2001</year>;<volume>20</volume>:<fpage>10</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr54-1947601912473479">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruediger</surname><given-names>R</given-names></name>
<name><surname>Pham</surname><given-names>HT</given-names></name>
<name><surname>Walter</surname><given-names>G</given-names></name>
</person-group>. <article-title>Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene</article-title>. <source>Oncogene</source>. <year>2001</year>;<volume>20</volume>:<fpage>1892</fpage>-<lpage>1899</lpage>.</citation>
</ref>
<ref id="bibr55-1947601912473479">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W</given-names></name>
<name><surname>Arroyo</surname><given-names>JD</given-names></name>
<name><surname>Timmons</surname><given-names>JC</given-names></name>
<name><surname>Possemato</surname><given-names>R</given-names></name>
<name><surname>Hahn</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity</article-title>. <source>Cancer Res</source>. <year>2005</year>;<volume>65</volume>:<fpage>8183</fpage>-<lpage>8192</lpage>.</citation>
</ref>
<ref id="bibr56-1947601912473479">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruediger</surname><given-names>R</given-names></name>
<name><surname>Ruiz</surname><given-names>J</given-names></name>
<name><surname>Walter</surname><given-names>G</given-names></name>
</person-group>. <article-title>Human cancer-associated mutations in the Aalpha subunit of protein phosphatase 2A increase lung cancer incidence in Aalpha knock-in and knockout mice</article-title>. <source>Mol Cell Biol</source>. <year>2011</year>;<volume>31</volume>:<fpage>3832</fpage>-<lpage>3844</lpage>.</citation>
</ref>
<ref id="bibr57-1947601912473479">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walter</surname><given-names>G</given-names></name>
<name><surname>Ruediger</surname><given-names>R</given-names></name>
</person-group>. <article-title>Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways</article-title>. <source>Cell Cycle</source>. <year>2012</year>;<volume>11</volume>:<fpage>451</fpage>-<lpage>459</lpage>.</citation>
</ref>
<ref id="bibr58-1947601912473479">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>W</given-names></name>
<name><surname>Kim</surname><given-names>ST</given-names></name>
<etal/>
</person-group>. <article-title>Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study</article-title>. <source>Cancer Genet</source>. <year>2011</year>;<volume>204</volume>:<fpage>375</fpage>-<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr59-1947601912473479">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mao</surname><given-names>X</given-names></name>
<name><surname>Boyd</surname><given-names>LK</given-names></name>
<name><surname>Yanez-Munoz</surname><given-names>RJ</given-names></name>
<etal/>
</person-group>. <article-title>Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer</article-title>. <source>Am J Cancer Res</source>. <year>2011</year>;<volume>1</volume>:<fpage>604</fpage>-<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr60-1947601912473479">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>BS</given-names></name>
<name><surname>Schultz</surname><given-names>N</given-names></name>
<name><surname>Hieronymus</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>L. Integrative genomic profiling of human prostate cancer</article-title>. <source>Cancer Cell</source>. <year>2010</year>;<volume>18</volume>:<fpage>11</fpage>-<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr61-1947601912473479">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>W</given-names></name>
<name><surname>Xie</surname><given-names>CC</given-names></name>
<name><surname>Zhu</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer</article-title>. <source>Neoplasia</source>. <year>2008</year>;<volume>10</volume>:<fpage>897</fpage>-<lpage>907</lpage>.</citation>
</ref>
<ref id="bibr62-1947601912473479">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>He</surname><given-names>WW</given-names></name>
<name><surname>Sciavolino</surname><given-names>PJ</given-names></name>
<name><surname>Wing</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer</article-title>. <source>Genomics</source>. <year>1997</year>;<volume>43</volume>:<fpage>69</fpage>-<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr63-1947601912473479">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhatia-Gaur</surname><given-names>R</given-names></name>
<name><surname>Donjacour</surname><given-names>AA</given-names></name>
<name><surname>Sciavolino</surname><given-names>PJ</given-names></name>
<etal/>
</person-group>. <article-title>Roles for Nkx3.1 in prostate development and cancer</article-title>. <source>Genes Dev</source>. <year>1999</year>;<volume>13</volume>:<fpage>966</fpage>-<lpage>977</lpage>.</citation>
</ref>
<ref id="bibr64-1947601912473479">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Curtis</surname><given-names>C</given-names></name>
<name><surname>Shah</surname><given-names>SP</given-names></name>
<name><surname>Chin</surname><given-names>SF</given-names></name>
<etal/>
</person-group>. <article-title>The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</article-title>. <source>Nature</source>. <year>2012</year>;<volume>486</volume>:<fpage>346</fpage>-<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr65-1947601912473479">
<label>65.</label>
<citation citation-type="journal">
<collab>Network TCGAR</collab>. <article-title>Integrated genomic analyses of ovarian carcinoma</article-title>. <source>Nature</source>. <year>2011</year>;<volume>474</volume>:<fpage>609</fpage>-<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr66-1947601912473479">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname><given-names>J</given-names></name>
<name><surname>Lee</surname><given-names>PL</given-names></name>
<name><surname>Li</surname><given-names>Z</given-names></name>
<etal/>
</person-group>. <article-title>B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer</article-title>. <source>Cancer Cell</source>. <year>2010</year>;<volume>18</volume>:<fpage>459</fpage>-<lpage>471</lpage>.</citation>
</ref>
<ref id="bibr67-1947601912473479">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muggerud</surname><given-names>AA</given-names></name>
<name><surname>Ronneberg</surname><given-names>JA</given-names></name>
<name><surname>Warnberg</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer</article-title>. <source>Breast Cancer Res</source>. <year>2010</year>;<volume>12</volume>:<fpage>R3</fpage>.</citation>
</ref>
<ref id="bibr68-1947601912473479">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dick</surname><given-names>FA</given-names></name>
</person-group>. <article-title>Structure-function analysis of the retinoblastoma tumor suppressor protein—is the whole a sum of its parts?</article-title> <source>Cell Div</source>. <year>2007</year>;<volume>2</volume>:<fpage>26</fpage>.</citation>
</ref>
<ref id="bibr69-1947601912473479">
<label>69.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Sotillo</surname><given-names>E</given-names></name>
<name><surname>Graña</surname><given-names>X</given-names></name>
</person-group>. <article-title>Escape from cellular quiescence</article-title>. In: <source>Cell cycle deregulation in cancer, contemporary cancer research</source> <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer Publishing</publisher-name>; <year>2010</year>. p. <fpage>3</fpage>-<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr70-1947601912473479">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rowland</surname><given-names>BD</given-names></name>
<name><surname>Bernards</surname><given-names>R</given-names></name>
</person-group>. <article-title>Re-evaluating cell-cycle regulation by E2Fs</article-title>. <source>Cell</source>. <year>2006</year>;<volume>127</volume>:<fpage>871</fpage>-<lpage>874</lpage>.</citation>
</ref>
<ref id="bibr71-1947601912473479">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Durfee</surname><given-names>T</given-names></name>
<name><surname>Becherer</surname><given-names>K</given-names></name>
<name><surname>Chen</surname><given-names>PL</given-names></name>
<etal/>
</person-group>. <article-title>The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit</article-title>. <source>Genes Dev</source>. <year>1993</year>;<volume>7</volume>:<fpage>555</fpage>-<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr72-1947601912473479">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nelson</surname><given-names>DA</given-names></name>
<name><surname>Krucher</surname><given-names>NA</given-names></name>
<name><surname>Ludlow</surname><given-names>JW</given-names></name>
</person-group>. <article-title>High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein</article-title>. <source>J Biol Chem</source>. <year>1997</year>;<volume>272</volume>:<fpage>4528</fpage>-<lpage>4535</lpage>.</citation>
</ref>
<ref id="bibr73-1947601912473479">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nelson</surname><given-names>DA</given-names></name>
<name><surname>Ludlow</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Characterization of the mitotic phase pRb-directed protein phosphatase activity</article-title>. <source>Oncogene</source>. <year>1997</year>;<volume>14</volume>:<fpage>2407</fpage>-<lpage>2415</lpage>.</citation>
</ref>
<ref id="bibr74-1947601912473479">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garriga</surname><given-names>J</given-names></name>
<name><surname>Jayaraman</surname><given-names>AL</given-names></name>
<name><surname>Limon</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>A dynamic equilibrium between CDKs and PP2A modulates phosphorylation of pRB, p107 and p130</article-title>. <source>Cell Cycle</source>. <year>2004</year>;<volume>3</volume>:<fpage>1320</fpage>-<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr75-1947601912473479">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>An</surname><given-names>B</given-names></name>
<name><surname>Dineley</surname><given-names>K</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Termin</surname><given-names>T</given-names></name>
<name><surname>Meijer</surname><given-names>L</given-names></name>
<name><surname>Dou</surname><given-names>Q</given-names></name>
</person-group>. <article-title>Involvement of RB kinases and phosphatases in life and death decisions</article-title>. <source>Oncol Rep</source>. <year>1997</year>;<volume>4</volume>:<fpage>1129</fpage>-<lpage>1134</lpage>.</citation>
</ref>
<ref id="bibr76-1947601912473479">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Magenta</surname><given-names>A</given-names></name>
<name><surname>Fasanaro</surname><given-names>P</given-names></name>
<name><surname>Romani</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Protein phosphatase 2A subunit PR70 interacts with pRb and mediates its dephosphorylation</article-title>. <source>Mol Cell Biol</source>. <year>2008</year>;<volume>28</volume>:<fpage>873</fpage>-<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr77-1947601912473479">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>P</given-names></name>
<name><surname>Jeffrey</surname><given-names>PD</given-names></name>
<name><surname>Shi</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation</article-title>. <source>Mol Cell</source>. <year>2008</year>;<volume>31</volume>:<fpage>873</fpage>-<lpage>885</lpage>.</citation>
</ref>
<ref id="bibr78-1947601912473479">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wurzenberger</surname><given-names>C</given-names></name>
<name><surname>Gerlich</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Phosphatases: providing safe passage through mitotic exit</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2011</year>;<volume>12</volume>:<fpage>469</fpage>-<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr79-1947601912473479">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmitz</surname><given-names>MH</given-names></name>
<name><surname>Held</surname><given-names>M</given-names></name>
<name><surname>Janssens</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Live-cell imaging RNAi screen identifies PP2A-B55alpha and importin-beta1 as key mitotic exit regulators in human cells</article-title>. <source>Nat Cell Biol</source>. <year>2009</year>;<volume>12</volume>:<fpage>886</fpage>-<lpage>893</lpage>.</citation>
</ref>
<ref id="bibr80-1947601912473479">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayer-Jaekel</surname><given-names>RE</given-names></name>
<name><surname>Ohkura</surname><given-names>H</given-names></name>
<name><surname>Ferrigno</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Drosophila mutants in the 55 kDa regulatory subunit of protein phosphatase 2A show strongly reduced ability to dephosphorylate substrates of p34cdc2</article-title>. <source>J Cell Sci</source>. <year>1994</year>;<volume>107</volume>(<issue>Pt 9</issue>):<fpage>2609</fpage>-<lpage>2616</lpage>.</citation>
</ref>
<ref id="bibr81-1947601912473479">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castilho</surname><given-names>PV</given-names></name>
<name><surname>Williams</surname><given-names>BC</given-names></name>
<name><surname>Mochida</surname><given-names>S</given-names></name>
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>Goldberg</surname><given-names>ML</given-names></name>
</person-group>. <article-title>The M phase kinase Greatwall (Gwl) promotes inactivation of PP2A/B55delta, a phosphatase directed against CDK phosphosites</article-title>. <source>Mol Biol Cell</source>. <year>2009</year>;<volume>20</volume>:<fpage>4777</fpage>-<lpage>4789</lpage>.</citation>
</ref>
<ref id="bibr82-1947601912473479">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vigneron</surname><given-names>S</given-names></name>
<name><surname>Brioudes</surname><given-names>E</given-names></name>
<name><surname>Burgess</surname><given-names>A</given-names></name>
<name><surname>Labbe</surname><given-names>JC</given-names></name>
<name><surname>Lorca</surname><given-names>T</given-names></name>
<name><surname>Castro</surname><given-names>A</given-names></name>
</person-group>. <article-title>Greatwall maintains mitosis through regulation of PP2A</article-title>. <source>EMBO J</source>. <year>2009</year>;<volume>28</volume>:<fpage>2786</fpage>-<lpage>2793</lpage>.</citation>
</ref>
<ref id="bibr83-1947601912473479">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mochida</surname><given-names>S</given-names></name>
<name><surname>Ikeo</surname><given-names>S</given-names></name>
<name><surname>Gannon</surname><given-names>J</given-names></name>
<name><surname>Hunt</surname><given-names>T</given-names></name>
</person-group>. <article-title>Regulated activity of PP2A-B55 delta is crucial for controlling entry into and exit from mitosis in Xenopus egg extracts</article-title>. <source>EMBO J</source>. <year>2009</year>;<volume>28</volume>:<fpage>2777</fpage>-<lpage>2785</lpage>.</citation>
</ref>
<ref id="bibr84-1947601912473479">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gharbi-Ayachi</surname><given-names>A</given-names></name>
<name><surname>Labbe</surname><given-names>JC</given-names></name>
<name><surname>Burgess</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A</article-title>. <source>Science</source>. <year>2010</year>;<volume>330</volume>:<fpage>1673</fpage>-<lpage>1677</lpage>.</citation>
</ref>
<ref id="bibr85-1947601912473479">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mochida</surname><given-names>S</given-names></name>
<name><surname>Maslen</surname><given-names>SL</given-names></name>
<name><surname>Skehel</surname><given-names>M</given-names></name>
<name><surname>Hunt</surname><given-names>T</given-names></name>
</person-group>. <article-title>Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis</article-title>. <source>Science</source>. <year>2010</year>;<volume>330</volume>:<fpage>1670</fpage>-<lpage>1673</lpage>.</citation>
</ref>
<ref id="bibr86-1947601912473479">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manchado</surname><given-names>E</given-names></name>
<name><surname>Guillamot</surname><given-names>M</given-names></name>
<name><surname>de Carcer</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta phosphatase</article-title>. <source>Cancer Cell</source>. <year>2010</year>;<volume>18</volume>:<fpage>641</fpage>-<lpage>654</lpage>.</citation>
</ref>
<ref id="bibr87-1947601912473479">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wallington-Beddoe</surname><given-names>CT</given-names></name>
<name><surname>Don</surname><given-names>AS</given-names></name>
<name><surname>Hewson</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e36429</fpage>.</citation>
</ref>
<ref id="bibr88-1947601912473479">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q</given-names></name>
<name><surname>Zhao</surname><given-names>X</given-names></name>
<name><surname>Frissora</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma</article-title>. <source>Blood</source>. <year>2008</year>;<volume>111</volume>:<fpage>275</fpage>-<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr89-1947601912473479">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neviani</surname><given-names>P</given-names></name>
<name><surname>Santhanam</surname><given-names>R</given-names></name>
<name><surname>Oaks</surname><given-names>JJ</given-names></name>
<etal/>
</person-group>. <article-title>FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia</article-title>. <source>J Clin Invest</source>. <year>2007</year>;<volume>117</volume>:<fpage>2408</fpage>-<lpage>2421</lpage>.</citation>
</ref>
<ref id="bibr90-1947601912473479">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>JD</given-names></name>
<name><surname>Takahara</surname><given-names>S</given-names></name>
<name><surname>Nonomura</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation</article-title>. <source>Prostate</source>. <year>1999</year>;<volume>40</volume>:<fpage>50</fpage>-<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr91-1947601912473479">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Azuma</surname><given-names>H</given-names></name>
<name><surname>Takahara</surname><given-names>S</given-names></name>
<name><surname>Ichimaru</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models</article-title>. <source>Cancer Res</source>. <year>2002</year>;<volume>62</volume>:<fpage>1410</fpage>-<lpage>1419</lpage>.</citation>
</ref>
<ref id="bibr92-1947601912473479">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>TK</given-names></name>
<name><surname>Man</surname><given-names>K</given-names></name>
<name><surname>Ho</surname><given-names>JW</given-names></name>
<etal/>
</person-group>. <article-title>FTY720; a promising agent for treatment of metastatic hepatocellular carcinoma</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>;<volume>11</volume>:<fpage>8458</fpage>-<lpage>8466</lpage>.</citation>
</ref>
<ref id="bibr93-1947601912473479">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsuoka</surname><given-names>Y</given-names></name>
<name><surname>Nagahara</surname><given-names>Y</given-names></name>
<name><surname>Ikekita</surname><given-names>M</given-names></name>
<name><surname>Shinomiya</surname><given-names>T</given-names></name>
</person-group>. <article-title>A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells</article-title>. <source>Br J Pharmacol</source>. <year>2003</year>;<volume>138</volume>:<fpage>1303</fpage>-<lpage>1312</lpage>.</citation>
</ref>
<ref id="bibr94-1947601912473479">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malumbres</surname><given-names>M</given-names></name>
<name><surname>Barbacid</surname><given-names>M</given-names></name>
</person-group>. <article-title>To cycle or not to cycle: a critical decision in cancer</article-title>. <source>Nat Rev Cancer</source>. <year>2001</year>;<volume>1</volume>:<fpage>222</fpage>-<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr95-1947601912473479">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McConechy</surname><given-names>MK</given-names></name>
<name><surname>Anglesio</surname><given-names>MS</given-names></name>
<name><surname>Kalloger</surname><given-names>SE</given-names></name>
<etal/>
</person-group>. <article-title>Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas</article-title>. <source>J Pathol</source>. <year>2011</year>;<volume>223</volume>:<fpage>567</fpage>-<lpage>573</lpage>.</citation>
</ref>
<ref id="bibr96-1947601912473479">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagendra</surname><given-names>DC</given-names></name>
<name><surname>Burke</surname><given-names>J</given-names></name>
<name><surname>Maxwell</surname><given-names>GL</given-names></name>
<name><surname>Risinger</surname><given-names>JI</given-names></name>
</person-group>. <article-title>PPP2R1A mutations are common in the serous type of endometrial cancer</article-title>. <source>Mol Carcinog</source>. <year>2012</year>;<volume>51</volume>:<fpage>826</fpage>-<lpage>831</lpage>.</citation>
</ref>
<ref id="bibr97-1947601912473479">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esplin</surname><given-names>ED</given-names></name>
<name><surname>Ramos</surname><given-names>P</given-names></name>
<name><surname>Martinez</surname><given-names>B</given-names></name>
<name><surname>Tomlinson</surname><given-names>GE</given-names></name>
<name><surname>Mumby</surname><given-names>MC</given-names></name>
<name><surname>Evans</surname><given-names>G</given-names></name>
</person-group>. <article-title>The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function</article-title>. <source>Genes Chromosomes Cancer</source>. <year>2006</year>;<volume>45</volume>:<fpage>182</fpage>-<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr98-1947601912473479">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takagi</surname><given-names>Y</given-names></name>
<name><surname>Futamura</surname><given-names>M</given-names></name>
<name><surname>Yamaguchi</surname><given-names>K</given-names></name>
<name><surname>Aoki</surname><given-names>S</given-names></name>
<name><surname>Takahashi</surname><given-names>T</given-names></name>
<name><surname>Saji</surname><given-names>S</given-names></name>
</person-group>. <article-title>Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers</article-title>. <source>Gut</source>. <year>2000</year>;<volume>47</volume>:<fpage>268</fpage>-<lpage>271</lpage>.</citation>
</ref>
<ref id="bibr99-1947601912473479">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chou</surname><given-names>HC</given-names></name>
<name><surname>Chen</surname><given-names>CH</given-names></name>
<name><surname>Lee</surname><given-names>HS</given-names></name>
<etal/>
</person-group>. <article-title>Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma</article-title>. <source>Cancer Lett</source>. <year>2007</year>;<volume>253</volume>:<fpage>138</fpage>-<lpage>143</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>